The current limitations of molecular diagnostics, such as PCR, do not allow for rapid screening and personalized follow-up of cancers and viral diseases. Healthcare professionals and institutions are therefore looking for simple, rapid and cost-effective tests for screening and monitoring patients. BrightSens Diagnostics will provide the solution to these needs by offering highly sensitive Point of Care tests. Our patented technology, with unique properties, is the result of 10 years of research supported by 2 ERC contracts with over 2M Euros. Our ultra-bright and ultra-sensitive fluorescent NanoAntennas amplify a detection signal. They allow direct measurement of very low concentrations of RNA - disease biomarkers - without enzymes, by simple fluorescence measurement. Our Point of Care tests will revolutionize molecular diagnostics." title="" class="btn" data-container="body" data-html="true" data-id="224232" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="BrightSens Diagnostics"> 625
Activities
Entity types
Location
11 Rue de l'Académie, 67000 Strasbourg, France
Strasbourg
France
Employees
Scale: 2-10
Estimated: 7
Engaged corporates
17Added in Motherbase
1 year, 2 months agoDisruptive Technology for Molecular Diagnostics based on Ultrabright Fluorescent Nanoparticles
The current limitations of molecular diagnostics, such as PCR, do not allow for rapid screening and personalized follow-up of cancers and viral diseases. Healthcare professionals and institutions are therefore looking for simple, rapid and cost-effective tests for screening and monitoring patients.
BrightSens Diagnostics will provide the solution to these needs by offering highly sensitive Point of Care tests. Our patented technology, with unique properties, is the result of 10 years of research supported by 2 ERC contracts with over 2M Euros.
Our ultra-bright and ultra-sensitive fluorescent NanoAntennas amplify a detection signal. They allow direct measurement of very low concentrations of RNA - disease biomarkers - without enzymes, by simple fluorescence measurement. Our Point of Care tests will revolutionize molecular diagnostics.
Brightsens Diagnostics Tests de diagnostic moléculaire simples, rapides, économiques pour le dépistage, le diagnostic et le suivi en point of care
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Caisse d’Epargne Banking | Caisse d’Epargne Banking | Other 13 Jan 2025 | | |
![]() Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 13 Jan 2025 | | |
![]() France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 13 Jan 2025 | | |
![]() | Gouvernement | Other 30 Nov 2022 | | |
![]() | Ministère des Solidarités | Other 30 Nov 2022 | | |
![]() Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Other 24 Dec 2024 | | |
![]() Ministry of Economy Government Administration | Ministry of Economy Government Administration | Other 13 Jan 2025 | | |
![]() Ministère de l'Intérieur Government Administration | Ministère de l'Intérieur Government Administration | Other 30 Nov 2022 | | |
![]() SATT CONECTUS Research, Research Services | SATT CONECTUS Research, Research Services | Other 13 Jan 2025 | | |
![]() CNRS Research, Research Services | CNRS Research, Research Services | Other 13 Jan 2025 | |